Schering Corporation

Pharmacopeia Drug Discovery, Inc.

Merck Sharp + Dohme Corp.

Pharmacopeia Inc.

Schering-plough Corporation

Chad E Knutson

Chad E Bennett

Viyyoor Moopil Girijavallabhan

Ronald J Doll

Brian Alexander McKittrick

Timothy J Guzi

Lawrence Wayne Dillard

Duane A Burnett

Michael P Dwyer

Kamil Paruch

Vinh D Tran

Ray Anthony James

Haengsoon Park

Zhen Min He

John W Clader

Hubert B Josien

Vincent Stewart Madison

Elizabeth M Smith

Wen-Lian Wu

Tin-Yau Chan

Dmitri A Pissarnitski

Hongmei Li

Jing Su

Theodros Asberom

Thierry Olivier Fischmann

Carmen S Alvarez

Zhiqiang Zhao

Haiqun Tang

Thavalakulamgara K Sasikumar

Joel M Harris

Ruo Xu

Thomas A Bara

Martin Domalski

Li Qiang

Hyunjin M Kim

Mark D McBriar

Murali Rajagopalan

David James Cole

Eugenia Y Kiselgof

William J Greenlee

Anandan Palani

Robert G Aslanian

Dong Xiao

Deen Tulshian

Henry M Vaccaro

Mary Ann Caplen

Tin Yau Chan

Peter Korakas

Mary Anne Caplen

Martin S Domalski

Thomas Bara

Thavalakulamgar K Sasikumar

This invention discloses novel gamma secretase inhibitors of the formula: Rand R, or Rand R, or Rand R, together with the atoms to which they are bound, can form a fused cycloalkyl or fused heterocycloalkyl ring. The cycloalkyl ring or the heterocycloalkyl ring can be optionally substituted with one or more substituents. One or more compounds of formula (I), or formulations comprising such compounds, may be useful, e.g. in treating Alzheimer's Disease.

Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors

This invention discloses novel gamma secretase inhibitors of the formula: Rand R, or Rand R, or Rand R, together with the atoms to which they are bound, can form a fused cycloalkyl or fused heterocycloalkyl ring. The cycloalkyl ring or the heterocycloalkyl ring can be optionally substituted with one or more substitutents. One or more compounds of formula (I), or formulations comprising such compounds, may be useful, e.g. in treating Alzheimer's Disease.

The present invention relates to Azetidinone Derivatives of structural formula 1: and compositions comprising an Azetidinone Derivative and methods for treating or preventing a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease, comprising administering to a patient an effective amount of an Azetidinone Derivative.

Azetidinone derivatives and methods of use thereof

In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J-J, X, Z, and R, R, and Rare as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease. 

Pyridothienopyridazinone derivatives as mGluR1 antagonists

Disclosed are compounds of the formula: and compounds of the formula: wherein R, R, R, R, R, u and v are as defined herein. Also disclosed are methods of treating pain (e.g., inflammatory pain, chronic pain, and neuropathic pain), methods of treating diabetes, and methods of inhibiting the absorption of cholesterol using compounds of formula I or IIA.

Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.

Trisubstituted 4-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors

Pyrazolopyrimidines as cyclin dependent kinase inhibitors

Growing community of inventors

Garwood, NJ, United States of America

Chad E Knutson